Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.
B. Schultheis
No relevant relationships to disclose
G. Folprecht
Consultant or Advisory Role - Merck Serono; Roche/Genentech
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Merck Serono
J. Kuhlmann
No relevant relationships to disclose
R. Ehrenberg
No relevant relationships to disclose
U. T. Hacker
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Novartis; Roche
Research Funding - Bayer
C. Kohne
No relevant relationships to disclose
M. Kornacker
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
O. Boix
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
T. Lin
Employment or Leadership Position - Bayer
J. Krauss
No relevant relationships to disclose
R. Fischer
No relevant relationships to disclose
S. Hamann
No relevant relationships to disclose
D. Strumberg
Consultant or Advisory Role - Bayer; Boehringer Ingelheim; Lilly; Pfizer; Roche
Honoraria - Bayer; Boehringer Ingelheim; Lilly; Pfizer; Roche
K. B. Mross
No relevant relationships to disclose